40 results
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
4:01pm
, listing of common stock on Nasdaq, and expanded U.S. operations.
Research and development (R&D) expenses were for $12.9 million USD for the twelve … are subject to conditions and may not occur, evaluations and judgments regarding Incannex’s research and development efforts, including any implications
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
drug candidates;
estimates regarding market size and related future growth rates;
our research and development (“R&D”) activities, including clinical … Authorities
The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising
8-K
EX-10.2
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
)), customer and supplier lists, improvements, protocols, processes, methods and techniques, research and development information, industry analyses … research and development tax incentives for the Company’s fiscal years ended June 30, 2023 and June 30, 2024;
(xv) all information requested
8-K
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
research and development Australian tax incentives, which are subject to a subordinated security interest. The subsidiaries will also guarantee the Notes
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
development and/or expansion of our products and therapies in our markets;
our research and development activities, including clinical testing … profitability in the future which makes our ability to continue as a going concern at risk.
Our research and development activities could be adversely
S-1
usz23amk33
3 Jul 24
IPO registration
6:29am
8-K
EX-99.1
6d5a3c r8qb4ur
16 Apr 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
9:30am
10-Q
25gdw vckxxa3
14 Feb 24
Quarterly report
6:16am
8-K
EX-14.1
22lstm5eu792
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
6-K
EX-99.1
4tibcky7hmlkmj2
26 Oct 23
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:02am
6-K
EX-99.1
5uaaznw2o5ma
1 Sep 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
bhvgcc1kgr6i me0xr
27 Jul 23
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
8:47pm
6-K
EX-99.1
q6f7c1l7xzo 4raf303
10 Jul 23
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
8:43am
6-K
EX-99.1
zqfv0v
26 Apr 23
Incannex Healthcare March 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
9:40pm
6-K
EX-99.1
87sk8n3m
13 Apr 23
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
9:23pm
6-K
EX-99.1
47fvophpxbwkwi
5 Dec 22
Report of Foreign Private Issuer
6:01am
6-K
EX-99.1
ax6hpb zxiff0c9
17 Nov 22
Report of Foreign Private Issuer
6:01am
20-F
295s7eyj
28 Oct 22
Annual report (foreign)
6:31am